Indaptus Therapeutics, Inc.
No enriched coverage for $INDP in the last 7 days.
No SEC Form 4 filings for $INDP in the last 30 days.
See all $INDP insider activity →Indaptus Therapeutics, Inc. (INDP) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Indaptus Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update NEW YORK (August 13, 2026) - Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a biotechnology company dedicated to
Indaptus Therapeutics (Nasdaq: INDP) reported Q2 2026 results and a corporate update. It raised about $12.0 million via a June 17 private placement at $0.60 per share. The company discontinued further Decoy20 enrollment and has no active clinical programs. Q2 R&D fell to ~$0.4M and net loss to ~$1.8M. Cash and short-term investments were ~$11.6M at June 30.
Indaptus Therapeutics, Inc. (INDP) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 ex10-1.htm EX-10.1 Exhibit 10.1 THE SECURITIES OFFERED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR REGISTERED OR QUALIFIED UNDER THE SECURITIES LAWS OF ANY STATE OR FOREIGN JURISDICTION OR APPROVED OR DISAPPROV
Recent INDP coverage spans financial news, corporate actions and earnings.
The filing is a capital-and-program reset: new financing improves liquidity, while Decoy20 is effectively wound down with no active clinical programs.
The financing plus Decoy20 wind-down materially changes the risk profile and runway, likely driving near-term valuation and trading volatility.
The 8-K discloses a sizable common-stock issuance at a stated price, which can pressure near-term valuation via dilution risk.
Limited actionable signal: the article offers no new catalyst beyond a prior strategic review and cash need disclosure.
Board/officer turnover and a COO-to-consultant transition can signal operational reset and may affect near-term execution risk.
alphai scores every news story that mentions INDP with an AI model for sentiment and relevance, and aggregates insider trades from Indaptus Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Indaptus Therapeutics, Inc. (INDP) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Indaptus Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update NEW YORK (August 13, 2026) - Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a biotechnology company dedicated to
4 min readIndaptus Therapeutics (Nasdaq: INDP) reported Q2 2026 results and a corporate update. It raised about $12.0 million via a June 17 private placement at $0.60 per share. The company discontinued further Decoy20 enrollment and has no active clinical programs. Q2 R&D fell to ~$0.4M and net loss to ~$1.8M. Cash and short-term investments were ~$11.6M at June 30.
4 min readIndaptus Therapeutics, Inc. (INDP) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 ex10-1.htm EX-10.1 Exhibit 10.1 THE SECURITIES OFFERED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR REGISTERED OR QUALIFIED UNDER THE SECURITIES LAWS OF ANY STATE OR FOREIGN JURISDICTION OR APPROVED OR DISAPPROV
4 min readuniQure (QURE) surged 78% after the FDA said the 3-year Phase I/II analysis for AMT-130 in Huntington’s could serve as primary evidence for an accelerated BLA; QURE plans to file in Q3 2026. Elicio (ELTX) rose 71% on Phase 2 AMPLIFY-7P responses. Lunai (LNAI) gained 40% on CEO updates; other biotech movers included CLPT, PLRZ and FTH.
5 min readIndaptus Therapeutics, Inc. (INDP) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001857044 0001857044 2026-06-01 2026-06-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report
3 min readIndaptus Therapeutics, Inc. has reported a net loss of $2.54 million for Q1 2026 and an accumulated deficit of $83.83 million, leading to a substantial doubt about its ability to continue as a going concern. The company's stockholders' equity decreased significantly, and it anticipates needing additional capital beyond Q2 2026, which will likely result in dilution for existing shareholders. Investors are warned of high market volatility and the potential for complete loss of investment given the company's clinical-stage status and limited operating history.
2 min readInvestor Yun Yao has converted preferred shares into 41.99 million common shares of Indaptus Therapeutics (INDP), becoming a more than 10% owner. The conversion involved Series AA and AAA Convertible Non-Redeemable Preferred Stock acquired on March 19, 2026, which were fully converted on March 23, 2026. This transaction strengthens Yao's stake in the biotechnology company.
2 min readNEW YORK, July 01, 2025 ( GLOBE NEWSWIRE ) -- Indaptus Therapeutics, Inc. ( Nasdaq: INDP ) ( "Indaptus" ) , a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced the additional sale of approximately $3.4 million in ...
2 min readU.S. stocks traded higher this morning, with the Dow Jones index gaining over 200 points on Monday. Following the market opening Monday, the Dow traded up 0.50% to 42,417.90 while the NASDAQ gained 0.61% to 19,566.92. The S&P 500 also rose, gaining, 0.62% to 6,004.66.
3 min readNEW YORK, June 13, 2025 ( GLOBE NEWSWIRE ) -- Indaptus Therapeutics, Inc. ( Nasdaq: INDP ) ( "Indaptus" ) , a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced the sale of approximately $2.3 million in aggregate ...
2 min read
